β-Cell Expansion for Therapeutic Compensation of Insulin Resistance in Type 2 Diabetes

Insulin resistance is the primary cause of type 2 diabetes. However, if compensated by increased insulin production, insulin resistance by itself does not lead to overt disease. Type 2 diabetes develops when this compensation is insufficient, due to defects in β-cell function and in regulation of th...

Descripción completa

Detalles Bibliográficos
Autor principal: Efrat, Shimon
Formato: Texto
Lenguaje:English
Publicado: 2003
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2480502/
https://www.ncbi.nlm.nih.gov/pubmed/12745664
http://dx.doi.org/10.1080/15438600303731
_version_ 1782157951616679936
author Efrat, Shimon
author_facet Efrat, Shimon
author_sort Efrat, Shimon
collection PubMed
description Insulin resistance is the primary cause of type 2 diabetes. However, if compensated by increased insulin production, insulin resistance by itself does not lead to overt disease. Type 2 diabetes develops when this compensation is insufficient, due to defects in β-cell function and in regulation of the β-cell mass. β-Cell transplantation, as well as approaches that replenish or preserve the endogenous β-cell mass, may facilitate the treatment of type 2 diabetes in patients requiring exogenous insulin.
format Text
id pubmed-2480502
institution National Center for Biotechnology Information
language English
publishDate 2003
record_format MEDLINE/PubMed
spelling pubmed-24805022008-08-18 β-Cell Expansion for Therapeutic Compensation of Insulin Resistance in Type 2 Diabetes Efrat, Shimon Int J Exp Diabesity Res Research Article Insulin resistance is the primary cause of type 2 diabetes. However, if compensated by increased insulin production, insulin resistance by itself does not lead to overt disease. Type 2 diabetes develops when this compensation is insufficient, due to defects in β-cell function and in regulation of the β-cell mass. β-Cell transplantation, as well as approaches that replenish or preserve the endogenous β-cell mass, may facilitate the treatment of type 2 diabetes in patients requiring exogenous insulin. 2003 /pmc/articles/PMC2480502/ /pubmed/12745664 http://dx.doi.org/10.1080/15438600303731 Text en Copyright © 2003 Hindawi Publishing Corporation. http://creativecommons.org/licenses/by/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Efrat, Shimon
β-Cell Expansion for Therapeutic Compensation of Insulin Resistance in Type 2 Diabetes
title β-Cell Expansion for Therapeutic Compensation of Insulin Resistance in Type 2 Diabetes
title_full β-Cell Expansion for Therapeutic Compensation of Insulin Resistance in Type 2 Diabetes
title_fullStr β-Cell Expansion for Therapeutic Compensation of Insulin Resistance in Type 2 Diabetes
title_full_unstemmed β-Cell Expansion for Therapeutic Compensation of Insulin Resistance in Type 2 Diabetes
title_short β-Cell Expansion for Therapeutic Compensation of Insulin Resistance in Type 2 Diabetes
title_sort β-cell expansion for therapeutic compensation of insulin resistance in type 2 diabetes
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2480502/
https://www.ncbi.nlm.nih.gov/pubmed/12745664
http://dx.doi.org/10.1080/15438600303731
work_keys_str_mv AT efratshimon bcellexpansionfortherapeuticcompensationofinsulinresistanceintype2diabetes

Ejemplares similares